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Conclusion: Obtained results do not permit to form robust 
conclusion concerning role of RT in the management of 
thymic tumors patient. Besides clear, unquestionable bad 
prognostic factors as bad PS, low differentiation, presence of 
local relapse, lung fibrosis, second malignancy or distant 
metastases, we found only one more - male sex, decreasing 
LC. 
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Purpose or Objective: In a UK Medical Research Council trial 
carried out before the widespread use of chemotherapy or 
CT-PET, palliative thoracic radiotherapy delivering 39 Gy in 
13 daily fractions conferred an overall survival (OS) benefit 
when compared to 17 Gy in 2 weekly fractions in good 
performance status patients with radically treatable NSCLC. 
To determine whether this benefit persisted with 
contemporary standards of staging and systemic therapy, we 
studied the outcomes of patients with locally 
advanced/metastatic NSCLC receiving palliative radiotherapy 
in our centre over a 2 year period. 
 
Material and Methods: The case records of 176 patients who 
received palliative thoracic radiotherapy in 2011 or 2012 
were reviewed retrospectively. Data collected included age, 
stage, performance status, dose/fractionation, additional 
treatments and survival. 
 
Results: 36 patients received high dose thoracic radiotherapy 
(HDTRT, 36-40 Gy in 12-15 fractions) and 140 received a 
lower dose (LDTRT), 20 Gy in 5 fractions. Median OS in the 
HDTRT group was 8.5 months and 5.5 months in the LDTRT 
group (hazard ratio 0.6, p <0.01). 12 patients received 
chemotherapy and HDTRT with median OS 12m vs 7m in the 
25 patients receiving chemotherapy and LDTRT. In those who 
received HDTRT alone, median OS was 6.5m vs 4m for LDTRT 
alone. In patients with stage II-III disease median OS was 
9.6m vs 6m for LDTRT. In those with stage IV disease, median 
OS was 8m for HDTRT vs 5m for LDTRT. In patients with 
performance status 0-2 median OS was 9m for HDTRT vs 6m 
for LDTRT, while in the two patients with performance status 
3 who were irradiated it was 1m with HDTRT vs 3m with 
LDTRT. 
 
Conclusion: This audit of contemporary practice suggests 
that the survival benefit of high dose palliative radiotherapy 
reported by Macbeth (Clin Oncol (R Coll Radiol). 1996;8:167-
75) persists with modern staging and systemic therapy 
practices, and may also extend to patients with small volume 
stage IV disease excluded from that trial, but not those with 
poor performance status. 
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Purpose or Objective: SBRT is the standard treatment of 
early stage inoperable NSCLC. Parenchymal changes (PC) 
after SBRT make it difficult the differential diagnosis 
between treatment effects and disease recurrence. The 
purpose of our study was to identify the radiographic 
features (High Risk Features: HRFS) with high specificity (SP) 
and sensitivity (SE) for early detection of recurrence. 
 
Material and Methods: We retrospectively evaluated patients 
treated with SBRT for inoperable early stage NSCLC. Median 
dose was 50 Gy in 5 fractions (range, 45-60 Gy /3-12 
fractions) prescribed to 80% isodose. All patients underwent 
chest computed tomography (CT) before SBRT and after 3, 6, 
12 months (thereafter annually). Using a chest CT scan 
radiological aspects according to Huang et al. classification 
(Huang et al., Radiother Oncol 2013;109:51-57) were 
evaluated. 18F FDG-PET was used in case of suspected tumor 
recurrence. 
 
Results: Forty-five patients were included, 34 males and 11 
females; mean age was 75.7 years (range, 60-86 years); 
77.8% of patients had stage IA disease and 22.2% stage IB 
with a mean follow-up of 21 months, local control was 69%. 
Benign acute CT changes (up to 6 months after SBRT) were 
observed in 34 patients (patchy consolidation was the most 
frequent) and late changes (after 6 months) in 44 patients 
(mass-like fibrosis was the most frequent). HRFs were 
identified in 20 patients, enlarging opacity at primary site in 
9 patients, enlargement after 12 months in 20 patients, 
bulging margin in 7 patients, disappearance of linear margin 
in 2 patients, loss of air bronchogram in 18 patients and 
cranial-caudal growth in 15 patients. These HRFs were 
individually significantly associated with local recurrence of 
the disease. The better predictor of relapse was enlargement 
opacity at 12 months (p <0.001) with SE: 84.6% and SP: 
71.8%. The presence of > 1 HRFS demonstrated a higher SE 
(93.3%) (p <0.02) with SP: 59.4%. 
 
Conclusion: Detection of HRFS is predictive of relapse with a 
SE increasing with the number of observed HRFs. This 
observation allows to better define the diagnostic algorithm 
in follow-up, suggesting to perform further exams only in 
patients with > 1 HRFS. 
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Purpose or Objective: Because there is a positive correlation 
between radiation dose and local control (LC) in non-small 
cell lung cancer (NSCLC) although with no impact on overall 
survival (OS) our institutional protocol allowed moderate 
radiotherapy dose escalation up to 70 - 74 Gy (BED: 84 - 88.8 
Gy) on the standard 60-66 Gy (BED: 72 - 79.2 Gy) providing 
that organs-at-risk are keep in tolerance. This retrospective 
study aims to assess the impact of dose escalation in clinical 
outcome when the duration of radiotherapy is taken in to 
account through the use of BED model corrected by time 
(tBED) 
 
Material and Methods: 78 consecutively patients with 
unresectable NSCLC were retrospectively analyzed. All were 
PET-CT staged and were treated with platinum-based 
chemotherapy (either concomitant or sequential) and 3DCRT. 
Two groups were compared according to prescribed dose 
level: Standard Dose Group (SD) n = 38 those receiving 
nominal prescribed BED ≤ 79.2 Gy and Escalated Dose Group 
(ED) n = 40 those receiving > nominal prescribed BED >79.2 
Gy. For both groups actual administered dose corrected for 
the duration of treatment (tBED) was calculated using the 
formula [tBED (Gy) = n d (1+d/ α/β) – KT] (Sinclair, IJROBP 
1999. 44:381) Multivariate Cox regression analysis was 
performed to identify significant predictors of OS, Disease 
Free Survival (DFS) and Thoracic Progression Free Survival 
(TPFS). For purposes of comparison a nominal prescribed 
dose of 60 Gy @2Gy in 39 days have a tBED = 44, 7 Gy. 
 
